Navigation Links
Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
Date:9/2/2008

to less than 15 minutes as we gain experience," adds Dr. Lagerwaard. "In these treatments the 'delivery' time was just 210 seconds per session." By comparison, conventional stereotactic treatment of three brain metastases using multiple dynamic conformal arcs takes more than 50 minutes from first beam on to last beam off, according to Dr. Lagerwaard.

At MIMA, Dr. Todd Scarbrough and his team treated a 77-year-old man with a history of small-cell lung cancer who had recently developed a brain metastasis. "Given his smoking and lung cancer history he was not considered a candidate for conventional neurosurgery," says Dr. Scarbrough. "We felt fast, non-invasive radiosurgery would be easier on this patient."

Joseph Ting, PhD, medical physicist, compared a RapidArc radiosurgery treatment plan with a non-coplanar IMRT plan using 14 stationary beams, which is how this patient would have been treated prior to RapidArc's availability.

"We were delighted to see that the RapidArc plan actually conformed the dose more closely to the size, shape and location of the tumor and could be delivered in three minutes instead of the 40 minutes needed for the 14-beam plan," Scarbrough said. The treatment was completed in four sessions over a four-day period.

Dr. Scarbrough adds, "Our plan is to use RapidArc any time the treatment plan gives us a dose distribution that is equal to or better than what we can get with standard IMRT, because RapidArc is so much faster. And that's much better for our patients."

In the August 15, 2008, issue of Clinical Cancer Research, (published online August 12) researchers from the University of Chicago Medical Center report that targeted radiation therapy had completely controlled all signs of cancer in 21 percent of patients who had five or fewer sites of metastatic disease.

Treatment planning analyses show that RapidArc matches or exceeds the precision of conventional IMRT systems and spares more of the healthy
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
3. NIH grants $750,000 to develop device to determine temperature of neonates brain
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Scientists create colorful brainbow images of the nervous system
6. Mouse Brain or Impressionist Painting?
7. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
8. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
10. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
11. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
Post Your Comments:
*Name:
*Comment:
*Email: